Abstract: Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.

Abstract: The present invention relates to novel DNA vaccines, configured to induce a robust and sustained immune response, and methods of use thereof. DNA vaccines proposed herein are configured to achieve this immune response by fusing the extracellular domain of a viral fusion protein to selected antigens or antigen-binding polypeptides. After the expression and secretion of the viral fusion-antigen protein from the initially transfected cells, the natural ability of the viral fusion protein to fuse to cell membranes and actively enter cells will allow for passive delivery of the fused target epitopes into neighboring cells, thus inducing a more robust immune response.

Abstract: Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.

Abstract: Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.

Abstract: Disclosed are genetic delivery systems that utilize genetic elements of the piggyBac family transposon system, and methods of introducing nucleic acid into target cells using the genetic delivery systems.

Abstract: The present invention is directed to methods for enhanced retroviral delivery of a nucleic acid to a target cell in vitro, ex vivo or in vivo, which involves increasing infectivity of a retrovirus carrying a transgene of interest to a target cell. In one particular aspect the invention relates to a method for increasing retroviral infectivity of target cells comprising culturing packaging cells transfected with retroviral vector containing a transgene of interest in medium containing a glucocorticoid receptor agonist or analog or derivative thereof present in the medium in an amount effective to increase titer of propagated retrovirus; and subsequently culturing a target cell in medium comprising the propagated retrovirus from a) and a glucocorticoid receptor antagonist or analog or derivative thereof present in the medium in an amount effective to increase target cell sensitivity to infection by the propagated retrovirus.